WOAG
WITHDRAWAL OF ATTORNEY GRANTED
07/30/2026
Back to search
Official data from USPTO
HEMOTEQ
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
HEMOTEQ
ST13
US500000076326915Class
5, 10, 40, 42
Filing
76326915
Registration
2931143
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
61
Latest update
07/31/2026
Trademark type
Word
Nice classes
5, 10, 40, 42
Filing date
10/18/2001
Registration date
03/08/2005
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/05/2025
Last transaction
07/31/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
First use anywhere
2001-02-00
First use in commerce
2001-02-00
Drawing code
1
Owner type
03
Owner location
WUERSELEN, DE
Examiner
WELLS, KELLEY L
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
HEMOTEQ AG
Hemoteq GmbH
Representatives
HEMOTEQ AG
Technical classification
Nice Classes
Class 5Class 10Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
heparin preparations and heparin derivatives combined with organic macromolecular substances with anti-thrombotic and/or anti-coagulative properties for use in coating artificial and natural surfaces for intracorporeal and extracorporeal circulation and for use in coating surgical implants; surgical implants comprising living tissue and organsheatsheart partslungsarteriesveinsaortas of mammalsespecially hearts of pigsheart valves of pigs and corpse veins; surgical implants comprising living tissue and organs coated with heparinheparin derivatives and macromolecular agentsheartsheart valveslungsarteriesveins and aortas of mammals * all goods exclusive of the use of antibodies *
Class 10
surgical implants comprising artificial materialartificial heart valvesheartslungsarteriesveins and aortas; medical instruments and accessories for use with the transfer and handling of bloodtubingvalvescontainersplastic bagscansneedlescatheters and for use with artificial surgical implants for the cardiovascular system and for extracorporeal circulation; surgical implants comprising artificial material; anti-thrombotic and/or anti-coagulative surgical implantsartificial surfacesartificial surfacesartificial heart valvesartificial heartsartificial lungsartificial arteriesartificial veinsartificial aortastubingvalvescontainersplastic bagscansneedlescathetersaccessories for use with the transfer and handling of blood for medical purposesespecially for intracorporeal and extracorporeal circulation; artificial surgical implants coated with heparinheparin derivatives and macromolecular agentsartificial heart valvesheartslungsarteriesveins and aortas; medical instruments and accessories for use with the transfer and handling of blood coated with heparinheparin derivatives and macromolecular agentstubingvalvescontainersplastic bagscansneedlescatheters and for use with artificial surgical implants for the cardiovascular system and for extracorporeal circulation * all goods exclusive of the use of antibodies *
Class 40
Commissioned coating services of artificial surgical implants and of surgical implants comprised of living tissue and organs with biopolymersespecially with heparinheparin derivatives and anti-thrombotic and/or coagulative macromolecular substances * all coating services exclusive of the use of antibodies *
Class 42
commissioned research and development services in the fields of surrogates for blood and blood substitutesblood productsblood-compatible materials and blood-compatible implants; commissioned research and development and consultation services in the fields of artificial surgical implants and of surgical implants comprised of living tissue and organs for the cardiovascular system and for extracorporeal circulationespecially coatings with heparinheparin derivatives and anti-thrombotic and/or anti-coagulative macromolecular substances; biochemicalpharmaceuticalmedical and scientific research services in the fields of surrogates for bloodblood substitutesblood productsblood-compatible materialblood-compatible implants and blood-compatible parts for the cardiovascular system and for extracorporeal circulation * all research and development services exclusive of the use of antibodies *
Publications
History of USPTO decisions and trademark events.
61 publications found
WOAR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
07/30/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/23/2026
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
07/23/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/23/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/23/2026
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
02/05/2025
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
02/05/2025
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
02/05/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/05/2025
E89R
TEAS SECTION 8 & 9 RECEIVED
10/11/2024
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
03/08/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/12/2018
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
04/25/2015
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
04/25/2015
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
04/25/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/23/2015
E89R
TEAS SECTION 8 & 9 RECEIVED
03/06/2015
CANT
CANCELLATION TERMINATED NO. 999999
07/14/2011
CAND
CANCELLATION DENIED NO. 999999
07/14/2011
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
03/31/2011
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
03/31/2011
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/31/2011
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/18/2011
E815
TEAS SECTION 8 & 15 RECEIVED
03/04/2011
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/21/2010
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
03/23/2010
PRAM
POST REGISTRATION ACTION MAILED - SEC. 7
02/25/2010
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/24/2010
ES7R
TEAS SECTION 7 REQUEST RECEIVED
02/23/2010
PETC
CANCELLATION INSTITUTED NO. 999999
02/02/2009
R.PR
REGISTERED-PRINCIPAL REGISTER
03/08/2005
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
10/22/2004
ALIE
ASSIGNED TO LIE
10/19/2004
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/13/2004
DOCK
ASSIGNED TO EXAMINER
10/13/2004
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/08/2004
IUAF
USE AMENDMENT FILED
09/24/2004
EISU
TEAS STATEMENT OF USE RECEIVED
09/24/2004
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
06/29/2004
PUBO
PUBLISHED FOR OPPOSITION
04/06/2004
EMRV
EMAIL RECEIVED
04/05/2004
NPUB
NOTICE OF PUBLICATION
03/17/2004
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/16/2004
44DD
SEC. 44(D) CLAIM DELETED
02/04/2004
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/07/2004
CNSL
LETTER OF SUSPENSION MAILED
11/19/2003
DOCK
ASSIGNED TO EXAMINER
11/18/2003
PCRC
PETITION TO DIRECTOR RECEIVED
10/29/2003
PAPER RECEIVED
10/29/2003
CFIT
CASE FILE IN TICRS
10/18/2003
CFIT
CASE FILE IN TICRS
10/16/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/22/2003
PAPER RECEIVED
09/22/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/17/2003
CNSI
INQUIRY AS TO SUSPENSION MAILED
03/19/2003
CNSL
LETTER OF SUSPENSION MAILED
08/26/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/03/2002
PAPER RECEIVED
07/03/2002
CNRT
NON-FINAL ACTION MAILED
12/31/2001
DOCK
ASSIGNED TO EXAMINER
12/27/2001
Continuous trademark protection
Get notified about every new filing that threatens HEMOTEQ or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.